A biobank of small cell lung cancer CDX models elucidates inter- and intratumoral phenotypic heterogeneity

DOI: 10.1038/s43018-020-0046-2

Preclinical Pharmacology

Abstract

Although small cell lung cancer (SCLC) is treated as a homogeneous disease, biopsies and preclinical models reveal heterogeneity in transcriptomes and morphology. SCLC subtypes were recently defined by neuroendocrine transcription factor (NETF) expression. Circulating-tumor-cell-derived explant models (CDX) recapitulate donor patients’ tumor morphology, diagnostic NE marker expression and chemotherapy responses. We describe a biobank of 38 CDX models, including six CDX pairs generated pretreatment and at disease progression revealing complex intra- and intertumoral heterogeneity. Transcriptomic analysis confirmed three of four previously described subtypes based on ASCL1, NEUROD1 and POU2F3 expression and identified a previously unreported subtype based on another NETF, ATOH1. We document evolution during disease progression exemplified by altered MYC and NOTCH gene expression, increased ‘variant’ cell morphology, and metastasis without strong evidence of epithelial to mesenchymal transition. This CDX biobank provides a research resource to facilitate SCLC personalized medicine.

Authors

Kathryn Simpson

Kathryn Simpson

Team Lead

Derrick Morgan

Derrick Morgan

Tissue Biomarkers Team Manager

Mitchell Revill

Mitchell Revill

Senior Scientific Officer

Melanie Galvin

Melanie Galvin

in vivo Team Manager

Caroline Dive

Caroline Dive

Director